Top of the morning to you. The middle of the week is upon us and, since you made it this far, why not forge ahead? After all, there is always light at the end of the proverbial tunnel. You never know what you may accomplish. So please join us as we celebrate this notion with a cup or three of delicious stimulation. Today, we are reaching for bourbon pecan. As always, we invite you to join us. Meanwhile, we have assembled a menu of tidbits to help you along. So please dig in. Have a smashing day and please feel free to forward any secrets you come across. Our “in basket” is always open. …
Biogen, a stalwart of the global drug industry for the past four decades, is perilously poised for 2022, STAT explains. The decisions to replace its chief executive officer and cut nearly all spending to market the Alzheimer’s treatment, Aduhelm, resolved some of the questions swirling around the embattled biotech. But the company is moving forward with a lame-duck chief executive officer, an interim chief scientist, and a board with a long history of gridlock. Its core business continues to deteriorate. And with Aduhelm placed largely on the sidelines, the best hope for growth is yet another risky Alzheimer’s therapy, one whose fate will have sweeping implications for Biogen’s future.
Moderna posted nearly $6 billion in sales of its Covid-19 vaccine in the first quarter of this year, and expects sales to be higher in the second half of the year than in the first six months, Reuters tells us. Sales of its vaccine, which recently gained authorization for a second booster dose in the U.S., rose to $5.9 billion in the first quarter from $1.7 billion a year ago. But investors and analysts have questioned whether vaccine sales are durable as an increasing number of people globally receive a complete vaccination course, countries relax their pandemic curbs, and the need for annual booster shots remains unclear.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
